The gastrointestinal stability of lipid nanocapsules

International Journal of Pharmaceutics

Volumn 379, Issue 2, 2009, Pages 260-265

  Roger, E ^a,b   Lagarce, F ^b,c   Benoit, J P ^b,c  

^a Ethypharm   (France)

^b INSERM   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Gastrointestinal tract; Lipid nanocapsules; Paclitaxel; Simulated media; Stability

Indexed keywords

LIPID NANOCAPSULE; NANOCAPSULE; PACLITAXEL; PANCREATIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG STABILITY; ENCAPSULATION; INTESTINE FLUID; PRIORITY JOURNAL; SIMULATION; STOMACH JUICE;

DRUG STABILITY; GASTRIC JUICE; GASTROINTESTINAL TRACT; INTESTINAL SECRETIONS; LIPIDS; NANOCAPSULES; SOLUBILITY;

EID: 68949218775     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.05.069     Document Type: Article

References (43)

1. Allard E., Passirani C., Garcion E., Pigeon P., Vessieres A., Jaouen G., and Benoit J.P. Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. J. Control. Release 130 (2008) 146-153
2. Borgström B. On the mechanism of pancreatic lipolysis of glycerides. Biochim. Biophys. Acta 13 (1954) 491-504
3. Bromberg L. Polymeric micelles in oral chemotherapy. J. Control. Release 128 (2008) 99-112
4. Constantinides P.P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 12 (1995) 1561-1572
5. des Rieux A., Fievez V., Momtaz M., Detrembleur C., Alonso-Sande M., Van Gelder J., Cauvin A., Schneider Y.J., and Preat V. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J. Control. Release 118 (2007) 294-302
6. Dressman J.B., and Lennernas H. Oral Drug Absorption: Prediction and Assessment vol. 106 (2000), Marcel Decker, Inc., New York
7. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 (1998) 11-22
8. Embleton J.K., and Pouton C.W. Structure and function of gastro-intestinal lipases. Adv. Drug Deliv. Rev. 25 (1997) 15-32
9. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., and Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15 (1998) 698-705
10. Gao P., Rush B.D., Pfund W.P., Huang T., Bauer J.M., Morozowich W., Kuo M.S., and Hageman M.J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 92 (2003) 2386-2398
11. García-Fuentes M., Torres D., and Alonso M.J. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B: Biointerfaces 27 (2003) 159-168
12. Garcion E., Lamprecht A., Heurtault B., Paillard A., Aubert-Pouessel A., Denizot B., Menei P., and Benoit J.P. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 5 (2006) 1710-1722
13. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19 (2002) 875-880
14. Horter D., and Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46 (2001) 75-87
15. Jantratid E., Janssen N., Chokshi H., Tang K., and Dressman J.B. Designing biorelevant dissolution tests for lipid formulations: case example-lipid suspension of RZ-50. Eur. J. Pharm. Biopharm. 69 (2008) 776-785
16. Jantratid E., Janssen N., Reppas C., and Dressman J.B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25 (2008) 1663-1676
17. Kalantzi L., Goumas K., Kalioras V., Abrahamsson B., Dressman J.B., and Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm. Res. 23 (2006) 165-176
18. Klein S., Butler J., Hempenstall J.M., Reppas C., and Dressman J.B. Media to simulate the postprandial stomach. I. Matching the physicochemical characteristics of standard breakfasts. J. Pharm. Pharmacol. 56 (2004) 605-610
19. Kuentz M. Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J. 10 (2008) 473-479
20. Lamprecht A., and Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release 112 (2006) 208-213
21. Landry F.B., Bazile D.V., Spenlehauer G., Veillard M., and Kreuter J. Degradation of poly(d,l-lactic acid) nanoparticles coated with albumin in model digestive fluids (USP XXII). Biomaterials 17 (1996) 715-723
22. Lindahl A., Ungell A.L., Knutson L., and Lennernas H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14 (1997) 497-502
23. Lipka E., and Amidon G.L. Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J. Control. Release 62 (1999) 41-49
24. Lobenberg R., Kramer J., Shah V.P., Amidon G.L., and Dressman J.B. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm. Res. 17 (2000) 439-444
25. Makino K., Ohshima H., and Kondo T. Transfer of protons from bulk solution to the surface of poly(l-lactide) microcapsules. J. Microencapsul. 3 (1986) 195-202
26. McConnell E.L., Fadda H.M., and Basit A.W. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm. 364 (2008) 213-226
27. Müller R.H., Rühl D., and Runge S.A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 144 (1996) 115-121
28. Nicolaides E., Symillides M., Dressman J.B., and Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 18 (2001) 380-388
29. Olbrich C., Kayser O., and Muller R.H. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage time and crystallinity. Int. J. Pharm. 237 (2002) 119-128
30. Olbrich C., and Müller R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm. 180 (1999) 31-39
31. Peltier S., Oger J.M., Lagarce F., Couet W., and Benoit J.P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23 (2006) 1243-1250
32. Porter C.J., Trevaskis N.L., and Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev. Drug Discov. 6 (2007) 231-248
33. Porter C.J.H., Pouton C.W., Cuine J.F., and Charman W.N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 60 (2008) 673-691
34. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11 Suppl. 2 (2000) S93-S98
35. Sahu A., Bora U., Kasoju N., and Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 4 (2008) 1752-1761
36. Schellens J.H., Malingre M.M., Kruijtzer C.M., Bardelmeijer H.A., van Tellingen O., Schinkel A.H., and Beijnen J.H. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur. J. Pharm. Sci. 12 (2000) 103-110
37. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., and van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2031-2035
38. Subramanian N., and Ghosal S.K. Enhancement of gastrointestinal absorption of poorly water soluble drugs via lipid based systems. Indian J. Exp. Biol. 42 (2004) 1056-1065
39. Tobío M., Sánchez A., Vila A., Soriano I., Evora C., Vila-Jato J.L., and Alonso M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B: Biointerfaces 18 (2000) 315-323
40. Trapani A., Garcia-Fuentes M., and Alonso M.J. Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology 19 (2008) 1-10
41. US.Pharmacopeia.XXIV, 2006. Vol. USP 29. Rockville, MD.
42. Vertzoni M., Fotaki N., Kostewicz E., Stippler E., Leuner C., Nicolaides E., Dressman J., and Reppas C. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 56 (2004) 453-462
43. Zhang Z., and Feng S.S. Self-assembled nanoparticles of poly(lactide)-vitamin E TPGS copolymers for oral chemotherapy. Int. J. Pharm. 324 (2006) 191-198